Premia Spine

Executive Summary

Premia Spine is an Israeli med-tech company pioneering a minimally invasive, injectable scaffold therapy for regenerating degenerated intervertebral discs. Its proprietary hydrogel platform delivers autologous mesenchymal stem cells and growth factors to restore disc height and function, aiming to eliminate the need for spinal fusion surgery. The company focuses on lumbar disc degeneration, a primary cause of chronic low-back pain, addressing a large unmet need in orthopedics and spinal disorders. Founded in 2020, Premia Spine has raised $30 million to advance its preclinical programs. While still in the preclinical stage, the company has demonstrated proof-of-concept in animal models and is progressing toward regulatory milestones. With a novel approach that combines regenerative medicine with a minimally invasive delivery system, Premia Spine has the potential to disrupt the $10 billion+ spinal surgery market. However, significant clinical, regulatory, and commercial hurdles remain. The company is expected to initiate first-in-human trials within the next 18-24 months, pending successful completion of ongoing preclinical studies and regulatory submissions.

Upcoming Catalysts (preview)

• Q4 2026Completion of pivotal preclinical efficacy study70% success
• H1 2027IND submission to FDA for first-in-human trial60% success
• Q2 2027First patient enrolled in Phase I clinical trial50% success